SimB16: Modeling Induced Immune System Response against B16-Melanoma
Figure 2
Activated OT-1 cells and systemic injection of anti-CD137 mAb show therapeutic synergy against B16-OVA melanoma.
Mice were subcutaneously implanted with B16-OVA cells on day 0 and treated on day 3 with 100 µg of rat IgG (control) or anti-CD137 mAb i.p. Mice also received on the same day activated or resting OT-1 cells i.v.